In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184
- 1 February 1995
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 39 (2) , 295-300
- https://doi.org/10.1128/aac.39.2.295
Abstract
A new pradimicin derivative, BMS-181184, was compared with amphotericin B and fluconazole against 249 strains from 35 fungal species to determine its antifungal spectrum. Antifungal testing was performed by the broth macrodilution reference method recommended by the National Committee for Clinical Laboratory Standards (document M27-P, 1992). BMS-181184 MICs for 97% of the 167 strains of Candida spp., Cryptococcus neoformans, Torulopsis glabrata, and Rhodotorula spp. tested were < or = 8 micrograms/ml, with a majority of MICs being 2 to 8 micrograms/ml. Similarly, for Aspergillus fumigatus and 89% of the 26 dermatophytes tested BMS-181184 MICs were < or = 8 micrograms/ml. BMS-181184 was fungicidal for the yeasts, dermatophytes, and most strains of A. fumigatus, although the reduction in cell counts was less for A. fumigatus than for the yeasts. BMS-181184 was active against Sporothrix schenckii, dematiaceous fungi, and some members of the non-Aspergillus hyaline hyphomycetes. BMS-181184, however, was not fungicidal against members of the family Dematiaceae. BMS-181184 lacked activity or had poorer activity (MICs, > or = 16 micrograms/ml) against Aspergillus niger, Aspergillus flavus, Malassezia furfur, Fusarium spp., Pseudallescheria boydii, Alternaria spp., Curvularia spp., Exserohilum mcginnisii, and the zygomycetes than against yeasts. The activity of BMS-181184 was minimally (twofold or less) affected by changes in testing conditions (pH, inoculum size, temperature, the presence of serum), testing methods (agar versus broth macrodilution), or test media (RPMI 1640, yeast morphology agar, high resolution test medium). Overall, our results indicate that BMS-181184 has a broad antifungal spectrum and that it is fungicidal to yeasts and, to a lesser extent, to filamentous fungi.Keywords
This publication has 13 references indexed in Scilit:
- Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1Antimicrobial Agents and Chemotherapy, 1993
- Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study GroupAntimicrobial Agents and Chemotherapy, 1993
- Emerging Fungal Pathogens in Immunocompromised Patients: Classification, Diagnosis, and ManagementClinical Infectious Diseases, 1993
- Impact of the changing epidemiology of fungal infections in the 1990sEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- In vitro and in vivo antifungal activities of BMS-181184.The Journal of Antibiotics, 1992
- In vitro and in vivo antifungal activities of BMY-28864, a water-soluble pradimicin derivativeAntimicrobial Agents and Chemotherapy, 1991
- Pradimicins A, B and C: New antifungal antibiotics. II. In vitro and in vivo biological activities.The Journal of Antibiotics, 1990
- In Vitro Potency and in Vivo Activity of AzolesAnnals of the New York Academy of Sciences, 1988
- Pradimicin, a novel class of potent antifungal antibiotics.The Journal of Antibiotics, 1988
- Cell Wall Chemistry, Morphogenesis, and Taxonomy of FungiAnnual Review of Microbiology, 1968